Published in J Biol Chem on November 01, 2004
Prostaglandins and cancer. Gut (2005) 3.44
Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology (2006) 2.78
Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo. Neoplasia (2006) 1.02
Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. Cancer Immun (2008) 0.99
Regulation of the Helicobacter pylori cellular receptor decay-accelerating factor. J Biol Chem (2008) 0.92
HEF1 is a crucial mediator of the proliferative effects of prostaglandin E(2) on colon cancer cells. Cancer Res (2010) 0.90
A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis. Genes Immun (2009) 0.88
Constitutive expression of murine decay-accelerating factor 1 is controlled by the transcription factor Sp1. J Immunol (2006) 0.81
Selective aryl hydrocarbon receptor modulator-mediated repression of CD55 expression induced by cytokine exposure. J Pharmacol Exp Ther (2012) 0.81
Gene expression profiling following constitutive activation of MEK1 and transformation of rat intestinal epithelial cells. Mol Cancer (2006) 0.80
Prostaglandin E2 affects T cell responses through modulation of CD46 expression. J Immunol (2012) 0.80
Suppression of tumorigenesis: modulation of inflammatory cytokines by oral administration of microencapsulated probiotic yogurt formulation. Int J Inflam (2010) 0.79
Prostaglandin E2 and Krüppel-like transcription factors synergistically induce the expression of decay-accelerating factor in intestinal epithelial cells. Immunology (2008) 0.77
1,25-Dihydroxyvitamin D3 promotes a sustained LPS-induced NF-κB-dependent expression of CD55 in human monocytic THP-1 cells. PLoS One (2012) 0.76
11β-Hydroxysteroid Dehydrogenase Type II is a Potential Target for Prevention of Colorectal Tumorigenesis. J Oncobiomarkers (2013) 0.75
Non-Steroidal Anti-Inflammatory Drugs in the Carcinogenesis of the Gastrointestinal Tract. Pharmaceuticals (Basel) (2010) 0.75
A tandem repeat in decay accelerating factor 1 is associated with severity of murine mercury-induced autoimmunity. Autoimmune Dis (2014) 0.75
COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol (2005) 3.15
Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem (2003) 2.65
Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell (2004) 2.60
15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem (2004) 2.55
CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med (2006) 2.30
NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med (2007) 2.19
Cyclooxygenase-2: a therapeutic target. Annu Rev Med (2002) 2.16
Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol (2005) 1.98
Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci U S A (2006) 1.97
Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat Med (2004) 1.89
Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression. Proc Natl Acad Sci U S A (2006) 1.84
The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology (2005) 1.83
COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol (2002) 1.80
CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell (2013) 1.71
Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res (2005) 1.68
Connecting COX-2 and Wnt in cancer. Cancer Cell (2006) 1.59
Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res (2003) 1.53
Aberrant cannabinoid signaling impairs oviductal transport of embryos. Nat Med (2004) 1.52
Targeted lipidomics using electron capture atmospheric pressure chemical ionization mass spectrometry. Rapid Commun Mass Spectrom (2003) 1.50
Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nat Med (2012) 1.47
Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res (2010) 1.44
15-Lipoxygenase metabolism of 2-arachidonylglycerol. Generation of a peroxisome proliferator-activated receptor alpha agonist. J Biol Chem (2002) 1.43
Cyclooxygenase as a target in lung cancer. Clin Cancer Res (2004) 1.43
The role of anti-inflammatory drugs in colorectal cancer. Annu Rev Med (2012) 1.40
Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res (2008) 1.39
Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2. Oncology (2005) 1.37
Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res (2005) 1.36
Pro-inflammatory prostaglandins and progression of colorectal cancer. Cancer Lett (2008) 1.32
Cyclooxygenase-1-derived PGE2 promotes cell motility via the G-protein-coupled EP4 receptor during vertebrate gastrulation. Genes Dev (2006) 1.28
Inflammation in the genesis and perpetuation of cancer: summary and recommendations from a national cancer institute-sponsored meeting. Cancer Res (2005) 1.27
Mechanisms of disease: Inflammatory mediators and cancer prevention. Nat Clin Pract Oncol (2005) 1.27
Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression. Cancer Res (2006) 1.26
The tumor microenvironment in colorectal carcinogenesis. Cancer Microenviron (2010) 1.23
Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. Cancer Res (2007) 1.17
Prostaglandin E2 regulates the nuclear receptor NR4A2 in colorectal cancer. J Biol Chem (2005) 1.15
Regulation of prostaglandin transporters in colorectal neoplasia. Cancer Prev Res (Phila) (2008) 1.15
Fishing for prostanoids: deciphering the developmental functions of cyclooxygenase-derived prostaglandins. Dev Biol (2005) 1.14
Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. Clin Cancer Res (2012) 1.08
β-Catenin and p120 mediate PPARδ-dependent proliferation induced by Helicobacter pylori in human and rodent epithelia. Gastroenterology (2011) 1.08
Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res (2002) 1.07
COX-2 in cancer--a player that's defining the rules. J Natl Cancer Inst (2002) 1.06
Cyclopentenone isoprostanes inhibit the inflammatory response in macrophages. J Biol Chem (2005) 1.05
Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. Proc Natl Acad Sci U S A (2004) 1.04
Peroxisome proliferator-activated receptor beta/delta expression and activation in lung cancer. Am J Respir Cell Mol Biol (2008) 1.04
Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer. Cancer Res (2008) 1.04
ANGPTL4 induction by prostaglandin E2 under hypoxic conditions promotes colorectal cancer progression. Cancer Res (2011) 1.02
An inflammatory mediator, prostaglandin E2, in colorectal cancer. Cancer J (2013) 1.01
WNT and cyclooxygenase-2 cross-talk accelerates adenoma growth. Cell Cycle (2004) 1.01
Cyclooxygenase-2 inhibitor therapy for the prevention of esophageal adenocarcinoma in Barrett's esophagus. J Natl Cancer Inst (2002) 1.01
Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer. Cancer Res (2007) 1.00
Peroxisome proliferator-activated receptor gamma and transforming growth factor-beta pathways inhibit intestinal epithelial cell growth by regulating levels of TSC-22. J Biol Chem (2002) 0.99
Cyclooxygenase-2-mediated metabolism of arachidonic acid to 15-oxo-eicosatetraenoic acid by rat intestinal epithelial cells. Chem Res Toxicol (2007) 0.99
Up-regulation of the enzymes involved in prostacyclin synthesis via Ras induces vascular endothelial growth factor. Gastroenterology (2004) 0.98
Urinary PGE-M: a promising cancer biomarker. Cancer Prev Res (Phila) (2013) 0.97
Stage-specific integration of maternal and embryonic peroxisome proliferator-activated receptor delta signaling is critical to pregnancy success. J Biol Chem (2007) 0.95
Prostaglandin Gbetagamma signaling stimulates gastrulation movements by limiting cell adhesion through Snai1a stabilization. Development (2010) 0.95
Inflammatory mediators and nuclear receptor signaling in colorectal cancer. Cell Cycle (2007) 0.94
Cyclooxygenase-2 and gastrointestinal cancer. Cancer J (2004) 0.94
Peroxisome proliferator-activated receptor gamma-mediated differentiation: a mutation in colon cancer cells reveals divergent and cell type-specific mechanisms. J Biol Chem (2003) 0.93
Aspirin and breast cancer prevention: the estrogen connection. JAMA (2004) 0.93
Associations between obesity and cancer: the role of fatty acid synthase. J Natl Cancer Inst (2012) 0.90
Measurement of eicosanoids in cancer tissues. Methods Enzymol (2007) 0.90
Emerging roles of beta-arrestins. Cell Cycle (2006) 0.90
HEF1 is a crucial mediator of the proliferative effects of prostaglandin E(2) on colon cancer cells. Cancer Res (2010) 0.90
Changes in cancer cell metabolism revealed by direct sample analysis with MALDI mass spectrometry. PLoS One (2013) 0.88
Novel agents in the treatment of lung cancer: conference summary statement. Clin Cancer Res (2004) 0.88
Oncogenic potential of MEK1 in rat intestinal epithelial cells is mediated via cyclooxygenase-2. Gastroenterology (2005) 0.88
15-LOX-1 inhibits p21 (Cip/WAF 1) expression by enhancing MEK-ERK 1/2 signaling in colon carcinoma cells. Prostaglandins Other Lipid Mediat (2004) 0.87
Controversies in COX-2 selective inhibition. J Rheumatol (2002) 0.86
The C-terminal domain LLKIL motif of CXCR2 is required for ligand-mediated polarization of early signals during chemotaxis. J Cell Sci (2004) 0.86
Nuclear orphan receptor NR4A2 modulates fatty acid oxidation pathways in colorectal cancer. J Biol Chem (2011) 0.86
Cyclooxygenase-2 selective inhibitors and prostate cancer: what is the clinical benefit? J Clin Oncol (2006) 0.82
AACR Cancer Progress Report 2012. Clin Cancer Res (2012) 0.82
Therapeutic potential of peroxisome proliferator-activated receptors in chronic inflammation and colorectal cancer. Gastroenterol Clin North Am (2010) 0.81
The cyclooxygenase-2 pathway as a target for treatment or prevention of cancer. Expert Opin Emerg Drugs (2003) 0.80
HIG2 promotes colorectal cancer progression via hypoxia-dependent and independent pathways. Cancer Lett (2013) 0.79
Evaluation of the whole prostaglandin biosynthetic pathway in lung cancer. Clin Cancer Res (2003) 0.79